PLRX:NASDAQPliant Therapeutics, Inc. Analysis

Pliant Therapeutics is trading well below its 20‑day and 50‑day simple moving averages, with the 20‑day SMA (≈1.21) under the 50‑day SMA (≈1.27), indicating a bearish price trend. The MACD line sits beneath its signal line and the histogram is negative, while the RSI at the low‑40s suggests limited upside momentum. Technical pressure is compounded by decreasing volume and a high 30‑day volatility of nearly 30%, plus a beta above 1.2, pointing to amplified price swings relative to the market.
On the fundamentals side, PLRX reports no revenue and negative earnings, resulting in a negative PE and a trailing EPS of –1.83. Nevertheless, the balance sheet shows modest cash (~$171 M) against low debt (~$29 M), yielding a low price‑to‑book of ~0.4 and an upside/downside potential of roughly 126% per analyst targets. Recent corporate updates note the initiation of dosing in the Phase 1b “FORTIFY” trial of PLN‑101095, which could serve as a catalyst if early data are positive. Given the extreme greed sentiment (Fear/Greed Index 89) and the high max drawdown of over 40%, the stock remains highly speculative despite its attractive valuation metrics.